Veracyte, Inc.

NasdaqGM:VCYT Stock Report

Market Cap: US$2.9b

Veracyte Future Growth

Future criteria checks 1/6

Veracyte is forecast to grow earnings and revenue by 10.9% and 9.9% per annum respectively. EPS is expected to grow by 7.6% per annum. Return on equity is forecast to be 8.2% in 3 years.

Key information

10.9%

Earnings growth rate

7.58%

EPS growth rate

Biotechs earnings growth22.2%
Revenue growth rate9.9%
Future return on equity8.21%
Analyst coverage

Good

Last updated26 Feb 2026

Recent future growth updates

Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next

May 10
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next

Recent updates

Veracyte: Profitable, De-Risked, And Ready To Run

Jan 16

Veracyte, Inc. (NASDAQ:VCYT) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Nov 22
Veracyte, Inc. (NASDAQ:VCYT) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Aug 30
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business

Jun 15
Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business

Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next

May 10
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next
User avatar

Decipher, Afirma And MRD Tests Will Broaden Future Markets

Veracyte’s Decipher test expansion and updated NCCN guidelines could drive significant revenue growth and market share in the prostate cancer segment.

Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality

Mar 08
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality

Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Mar 04
Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price

Jan 09
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price

Veracyte: Getting Frothy

Dec 11

Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Dec 01
Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%

Aug 18
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%

Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 09
Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price

Jul 02
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Jun 06
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 09
Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Earnings and Revenue Growth Forecasts

NasdaqGM:VCYT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028719961411486
12/31/20276489111914612
12/31/2026576749612012
12/31/202551766127136N/A
9/30/20254953098108N/A
6/30/2025479268493N/A
3/31/2025463337889N/A
12/31/2024446246475N/A
9/30/2024425-95666N/A
6/30/2024400-544050N/A
3/31/2024375-682637N/A
12/31/2023361-743444N/A
9/30/2023343-502938N/A
6/30/2023329-292331N/A
3/31/2023311-30714N/A
12/31/2022297-37-18N/A
9/30/2022284-43-16N/A
6/30/2022268-49-10-2N/A
3/31/2022251-48-70N/A
12/31/2021220-76-37-32N/A
9/30/2021187-73-43-38N/A
6/30/2021157-63-39-35N/A
3/31/2021123-65-48-45N/A
12/31/2020117-35-13-10N/A
9/30/2020113-34-13-10N/A
6/30/2020113-31-16-13N/A
3/31/2020122-22-10-8N/A
12/31/2019120-13-6-3N/A
9/30/2019116-8N/A-6N/A
6/30/2019109-12N/A-6N/A
3/31/2019101-16N/A-7N/A
12/31/201892-23N/A-14N/A
9/30/201886-28N/A-18N/A
6/30/201880-31N/A-21N/A
3/31/201876-32N/A-23N/A
12/31/201772-31N/A-24N/A
9/30/201771-27N/A-22N/A
6/30/201772-26N/A-25N/A
3/31/201768-29N/A-27N/A
12/31/201665-31N/A-28N/A
9/30/201661-35N/A-27N/A
6/30/201655-38N/A-23N/A
3/31/201652-36N/A-27N/A
12/31/201550-34N/A-27N/A
9/30/201548-34N/A-33N/A
6/30/201545-33N/A-35N/A
3/31/201542-30N/A-30N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VCYT's forecast earnings growth (10.9% per year) is above the savings rate (3.4%).

Earnings vs Market: VCYT's earnings (10.9% per year) are forecast to grow slower than the US market (15.5% per year).

High Growth Earnings: VCYT's earnings are forecast to grow, but not significantly.

Revenue vs Market: VCYT's revenue (9.9% per year) is forecast to grow slower than the US market (10.2% per year).

High Growth Revenue: VCYT's revenue (9.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: VCYT's Return on Equity is forecast to be low in 3 years time (8.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/02 06:52
End of Day Share Price 2026/03/02 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Veracyte, Inc. is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paul KnightBrean Capital Historical (Janney Montgomery)
Sung Ji NamBTIG
Kyle MiksonCanaccord Genuity